Securities code: Shanghai Rightongene Biotechnology Co.Ltd(688217) securities abbreviation: Shanghai Rightongene Biotechnology Co.Ltd(688217) Shanghai Rightongene Biotechnology Co.Ltd(688217)
2021 annual general meeting
Meeting materials
May 2022
catalogue
Notes to the 2021 annual general meeting of shareholders 3 agenda of the annual general meeting of shareholders in 2001 5 proposal of the annual general meeting of shareholders in 2001 seven
Proposal 1: proposal on the work report of the board of directors in 2021 seven
Proposal 2: proposal on the work report of the board of supervisors in 2021 eight
Proposal 3: proposal on the work report of independent directors in 2021 nine
Proposal 4: proposal on the financial statement report of 2021 ten
Proposal 5: proposal on the financial budget report of 2022 eleven
Proposal 6: proposal on the profit distribution plan for 2021 twelve
Proposal 7: proposal on renewing the appointment of accounting firms fifteen
Proposal 8: proposal on the 2021 annual report and its summary sixteen
Proposal 9: proposal on the remuneration scheme of directors in 2022 seventeen
Proposal 10: proposal on the remuneration scheme of supervisors in 202218 Annex I: Shanghai Rightongene Biotechnology Co.Ltd(688217) 2021 annual work report of the board of Directors 19 Annex II: Shanghai Rightongene Biotechnology Co.Ltd(688217) 2021 annual work report of the board of supervisors twenty-eight
Annex III: Shanghai Rightongene Biotechnology Co.Ltd(688217) 2021 annual financial statement report thirty-three
Annex II: Shanghai Rightongene Biotechnology Co.Ltd(688217) 2022 annual financial budget report forty
Shanghai Rightongene Biotechnology Co.Ltd(688217)
Notes to the 2021 annual general meeting of shareholders
In order to safeguard the legitimate rights and interests of the majority of investors, ensure the normal order and efficiency of the shareholders’ meeting of Shanghai Rightongene Biotechnology Co.Ltd(688217) (hereinafter referred to as “the company” or ” Shanghai Rightongene Biotechnology Co.Ltd(688217) “), and ensure the shareholders to exercise their rights according to law during the shareholders’ meeting, the instructions to the meeting are hereby formulated in accordance with the company law, the rules of the shareholders’ meeting of listed companies of the CSRC, the rules of procedure of the shareholders’ meeting of the company and other relevant provisions:
1、 The company is responsible for the agenda arrangement and affairs of the general meeting of shareholders. In order to confirm the attendance qualification of shareholders or their agents or other attendees, the meeting staff will check the identity of the attendees and ask the verified ones to cooperate.
2、 Shareholders and shareholders’ agents attending the meeting shall go through the sign in procedures at the meeting site half an hour before the meeting, and show the securities account card, ID documents or copies of business license / registration certificate (stamped with official seal), power of attorney, etc. as required. A copy of the above registration materials shall be provided, the copy of personal registration materials shall be signed by individuals, and the copy of legal representative certification documents shall be stamped with the official seal of the company, Attend the meeting after verification. After the commencement of the meeting, the chairman of the meeting shall announce the number of shareholders attending the meeting and the total number of voting shares held by them. After that, the shareholders entering the meeting have no right to participate in the on-site voting.
3、 The meeting deliberated and voted on proposals in the order listed in the meeting notice.
4、 Shareholders and their agents enjoy the right to speak, question and vote according to law. Shareholders and their agents attending the general meeting of shareholders shall earnestly perform their legal obligations, shall not infringe upon the legitimate rights and interests of the company and other shareholders and their agents, and shall not disturb the normal order of the general meeting of shareholders.
5、 Shareholders and their proxies who request to speak shall speak in accordance with the agenda of the meeting and with the permission of the chairman of the meeting. When more than one shareholder and shareholder’s agent request to speak at the same time, the one who raises his hand first shall speak; When the order cannot be determined, the host shall designate the speaker. The speeches or questions of shareholders and their agents shall focus on the topics of the general meeting of shareholders, be concise and concise, and the time shall not exceed 5 minutes.
6、 When shareholders and their proxies request to speak, they shall not interrupt the report of the meeting reporter or the speeches of other shareholders and their proxies. When voting at the general meeting of shareholders, shareholders and their proxies will no longer speak. If shareholders and their agents violate the above provisions, the chairman of the meeting has the right to refuse or stop them.
7、 The moderator may arrange the company’s directors and senior managers to answer the questions raised by the shareholders. The moderator or its designated relevant personnel have the right to refuse to answer the questions that have nothing to do with the topics of the shareholders’ meeting, may disclose the company’s business secrets and / or insider information, and damage the common interests of the company and shareholders.
8、 Shareholders and their proxies attending the general meeting of shareholders shall express one of the following opinions on the proposal submitted for voting: agree, oppose or abstain. Shareholders and their proxies attending the on-site meeting must sign the names of shareholders on the votes. The votes that are not filled in, wrongly filled in, illegible and not cast shall be deemed as the voters’ waiver of voting rights, and the voting results of their shares shall be counted as “waiver”.
9、 The general meeting of shareholders adopts the combination of on-site voting and online voting, and the announcement of the resolution of the general meeting of shareholders is issued in combination with the voting results of on-site voting and online voting.
10、 The general meeting of shareholders was witnessed by the practicing lawyer of the law firm hired by the company and issued a legal opinion.
11、 During the meeting, the participants shall pay attention to maintaining the order of the meeting place and shall not walk around at will. The mobile phone shall be adjusted to the silent state, and personal recording, video recording and photographing shall be refused. The meeting staff shall have the right to stop the acts that interfere with the normal order of the meeting or infringe on the legitimate rights and interests of other shareholders and report to the relevant departments for handling.
12、 The expenses incurred by shareholders and their agents attending the general meeting of shareholders shall be borne by the shareholders themselves. The company will not give gifts to shareholders participating in the general meeting of shareholders, and will not be responsible for arranging the accommodation of shareholders participating in the general meeting of shareholders, so as to treat all shareholders equally.
13、 Special reminder: in order to cooperate with the current arrangements for the prevention and control of the novel coronavirus epidemic, the company recommends that all shareholders participate in the shareholders’ meeting by means of online voting. If you really need to attend the meeting on site, please make sure that you have normal body temperature, no respiratory discomfort and other symptoms, and strictly abide by Shanghai epidemic prevention and control policies and measures. You must wear masks and other protective equipment on the whole day of the meeting and do a good job in personal protection. On the day of the meeting, the company conducted relevant inspection on the participants in accordance with the latest local epidemic prevention and control policies. Please cooperate.
Shanghai Rightongene Biotechnology Co.Ltd(688217)
Agenda of 2021 annual general meeting of shareholders
1、 Meeting time, place and voting method
1. On site meeting time: 14:30, May 10, 2022
2. Venue of the on-site meeting: room Shanghai Rightongene Biotechnology Co.Ltd(688217) of building 3, No. 6055, Jinhai Road, Fengxian District, Shanghai 3. Convener of the meeting: Shanghai Rightongene Biotechnology Co.Ltd(688217) board of directors 4. Moderator of the meeting: Ms. Xiong Hui, chairman 5. Online voting system, start and end time and voting time
Online voting system: online voting system for shareholders’ meeting of Shanghai Stock Exchange
Starting and ending time of online voting: from May 10, 2022 to May 10, 2022
The online voting system of Shanghai Stock Exchange is adopted. The voting time through the trading system voting platform is the trading time period on the day of the general meeting of shareholders, i.e. 9:15-9:25, 9:30-11:30, 13:00-15:00; The voting time through the Internet voting platform is 9:15-15:00 on the day of the general meeting of shareholders.
2、 Agenda of the meeting: (I) participants sign in and receive meeting materials (II) the host announces the beginning of the meeting, reports the number of shareholders attending the on-site meeting and the number of voting rights held, and introduces the participants and non voting participants of the on-site meeting
(III) the host read out the instructions to the general meeting of shareholders (IV) recommend the vote counter and the vote scrutinizer (V) review each proposal item by item and the name of non cumulative voting proposal
1 proposal on the work report of the board of directors in 2021
2 proposal on the work report of the board of supervisors in 2021
2023 annual report of independent directors
4. Proposal on financial final accounts report of 2021
5 proposal on financial budget report of 2022
6 proposal on 2021 profit distribution plan
7. Proposal on re employment of accounting firm
8. Proposal on the 2021 annual report and its summary
9 proposal on Directors’ remuneration scheme in 2022
10 proposal on the remuneration scheme of supervisors in 2022
(VI) speeches and questions of shareholders and their proxies (VII) voting of shareholders and their proxies on various proposals (VIII) adjournment, vote counter The scrutineer counts the on-site voting results (IX) summarizes the online voting and on-site voting results (x) the host reads out the voting results and resolutions of the general meeting of shareholders (XI) the witness lawyer reads out the legal opinions of the general meeting of shareholders (XII) signs the meeting documents (XIII) the host announces the end of the general meeting of shareholders
Shanghai Rightongene Biotechnology Co.Ltd(688217)
Proposal of 2021 annual general meeting of shareholders
Proposal 1 proposal on the work report of the board of directors in 2021 shareholders and shareholders’ agents:
In 2021, the board of directors of Shanghai Rightongene Biotechnology Co.Ltd(688217) (hereinafter referred to as “the company”) earnestly performed the duties of the board of directors entrusted by the general meeting of shareholders in strict accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China and other relevant laws and regulations, normative documents and the articles of association, and carried out all work diligently and responsibly to promote the sustainable, healthy and stable development of the company. Accordingly, the board of directors of the company formulated the work report of the board of directors for Shanghai Rightongene Biotechnology Co.Ltd(688217) 2021. See Annex I for details.
This proposal has been deliberated and adopted at the fourth meeting of the second board of directors held on April 18, 2022. It is hereby submitted to the general meeting of shareholders for deliberation, and all shareholders and their proxies are invited to deliberate.
Annex I: work report of the board of directors Shanghai Rightongene Biotechnology Co.Ltd(688217) 2021 proposal of the board of directors Shanghai Rightongene Biotechnology Co.Ltd(688217) May 10, 2022 proposal on the work report of the board of supervisors 2021 shareholders and shareholder agents:
In 2021, the board of supervisors of Shanghai Rightongene Biotechnology Co.Ltd(688217) (hereinafter referred to as “the company”) conscientiously performed its supervisory duties in strict accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China and other relevant laws and regulations, normative documents and the articles of association, actively participated in the review of major decision-making matters and important economic activities of the company, put forward opinions and suggestions, and made comments and suggestions to the directors The management has effectively supervised the performance of the company’s duties, inspected the company’s operation and financial status from time to time, and actively safeguarded the rights and interests of all shareholders. Accordingly, the board of supervisors of the company formulated the work report of the board of supervisors for Shanghai Rightongene Biotechnology Co.Ltd(688217) 2021. See Annex II for details. This proposal has been deliberated and adopted at the fourth meeting of the second board of supervisors held on April 18, 2022. It is hereby submitted to the general meeting of shareholders for deliberation, and all shareholders and their proxies are invited to deliberate.
Annex II: work report of Shanghai Rightongene Biotechnology Co.Ltd(688217) 2021 board of supervisors Shanghai Rightongene Biotechnology Co.Ltd(688217) board of supervisors proposal III on work report of independent directors in 2021 on May 10, 2022 shareholders and shareholder agents:
In 2021, the independent directors of Shanghai Rightongene Biotechnology Co.Ltd(688217) (hereinafter referred to as “the company”) performed their duties honestly, diligently and independently in strict accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China and other relevant laws and regulations, normative documents and the articles of association, actively attended relevant meetings, carefully considered various proposals of the board of directors and expressed independent opinions on major issues of the company, Effectively safeguard the legitimate rights and interests of the company and public shareholders, promote the standardized operation of the company, and give full play to the role of independent directors and special committees.
For details, please refer to the website of Shanghai Stock Exchange on April 20, 2022
（www.sse.com.cn.） Report on the work of independent directors in 2021 disclosed.
This proposal has been deliberated and adopted at the fourth meeting of the second board of directors held on April 18, 2022. It is hereby submitted to the general meeting of shareholders for deliberation, and all shareholders and their proxies are invited to deliberate.
Shanghai Rightongene Biotechnology Co.Ltd(688217) proposal IV of the board of directors on May 10, 2022 on the financial statement report of 2021 shareholders and shareholders’ agents:
Shanghai Rightongene Biotechnology Co.Ltd(688217) (hereinafter referred to as “the company”) according to the financial situation and operating results of the company in 2021, the board of directors of the company formulated the final financial statement report of Shanghai Rightongene Biotechnology Co.Ltd(688217) 2021. See Annex III for details.
This proposal has been approved in April 2022
